Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,726 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.
Zhang Q, Zhang J, Zhong H, Yuan Y, Yang L, Zhang Q, Ji D, Gong J, Li J, Yao Z, Qi C, Wang J, Lu L, Shi M, Qian X, Shen L, Li J, Hu X. Zhang Q, et al. Among authors: ji d. Cancer Immunol Immunother. 2023 Aug;72(8):2729-2739. doi: 10.1007/s00262-023-03434-2. Epub 2023 Apr 28. Cancer Immunol Immunother. 2023. PMID: 37115210 Free PMC article. Clinical Trial.
[A phase Ⅰ dose-escalating trial of pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine and prednisone for aggressive non-Hodgkin lymphoma].
Shen WN, Ji DM, Xue K, Zhang QL, Lyu FF, Hong XN, Cao JN, Guo Y. Shen WN, et al. Among authors: ji dm. Zhonghua Xue Ye Xue Za Zhi. 2016 Dec 14;37(12):1044-1048. doi: 10.3760/cma.j.issn.0253-2727.2016.12.007. Zhonghua Xue Ye Xue Za Zhi. 2016. PMID: 28088967 Free PMC article. Clinical Trial. Chinese.
A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy.
Ji D, Shen W, Zhang J, Cao J, Li W, Lam LH, Wu F, Wang B, Li Z, Sun G, Hu X, Chen SC. Ji D, et al. Medicine (Baltimore). 2020 Oct 30;99(44):e22886. doi: 10.1097/MD.0000000000022886. Medicine (Baltimore). 2020. PMID: 33126339 Free PMC article. Clinical Trial.
First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study.
Zhang J, Ji D, Cai L, Yao H, Yan M, Wang X, Shen W, Du Y, Pang H, Lai X, Zeng H, Huang J, Sun Y, Peng X, Xu J, Yang J, Yang F, Xu T, Hu X. Zhang J, et al. Among authors: ji d. Clin Cancer Res. 2022 Feb 15;28(4):618-628. doi: 10.1158/1078-0432.CCR-21-2827. Clin Cancer Res. 2022. PMID: 34844975 Clinical Trial.
1,726 results